Drug intelligence / Profile preview

ginsenoside Rh4

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

Ginsenoside Rh4 is a triterpenoid saponin isolated primarily from Panax ginseng (Korean red ginseng), Panax notoginseng, and Panax vietnamensis. It exhibits a variety of pharmacological activities, including anti-tumor, anti-inflammatory, anti-oxidative, gastroprotective, and immunomodulatory effects. Its mechanisms of action are diverse—Rh4 has been shown to reverse multidrug resistance in tumor cells by downregulating ABCB1 expression and inhibiting the PI3K/AKT pathway, thereby enhancing chemotherapy efficacy. It inhibits cancer cell proliferation by activating the ROS/p53 signaling pathway and triggering ferroptosis and autophagy. Rh4 modulates several cell survival and death signaling cascades such as NF-κB, STAT3, and JAK-STAT, and induces apoptosis by activating the death receptor Fas and increasing cytochrome C release. As an adjunct to chemotherapy, Rh4 can alleviate chemotherapy-induced gastrointestinal mucositis by modulating the gut microbiota and restoring intestinal barrier function, particularly via the TGR5-TLR4-NF-κB pathway. Rh4 also has demonstrated protective effects against gastric ulcers and hepatic lipid metabolism disorders in various in vivo models[1][2][3][4][5][7][9][10].

Other names
ginsenoside Rh(4)6-O-beta-D-glucopyranosyldammar-20(22),24-diene-3 beta,6 alpha,12 beta-triol
02

Targets

AKT (RAC-alpha serine/threonine-protein kinase)ABCB1 (P-glycoprotein)GPBAR1IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)NF-κBPI3K (Phosphoinositide-3-kinase regulatory subunit 6)STAT3 (Signal Transducer and Activator of Transcription 3)TLR4 (Toll-like receptor 4)TNFA (Tumor necrosis factor alpha (soluble))TP53 (Cellular Tumor Antigen p53 R175H)JAK (Janus kinase family)

Beyond the preview

Go deeper on ginsenoside Rh4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ginsenoside Rh4.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call